Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Reduceret dosis strålebehandling til behandling af indolent non-Hodgkin lymfom

6. november 2026 opdateret af: Mayo Clinic

Reduceret dosis hypofraktioneret strålebehandling (3Gy x 3 fraktioner) for indolent non-Hodgkin lymfom (POSEIDON): Et multisite fase 2 randomiseret forsøg

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

I. To show that the experimental arm [9 gray (Gy) in 3 fractions, 8 Gy in 2 fractions, or 10 Gy in 5 fractions] has significantly reduced acute toxicity (grade ≥ 2 adverse events at least possibly related to radiation treatment within 14 days after the end of radiation treatment [according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0] compared to 24 Gy in 12 fractions.

SECONDARY OBJECTIVES:

I. To evaluate patient reported quality of life. II. To evaluate response rate. III. To evaluate local control rate. IV. To evaluate relapse-free survival.

EXPLORATORY OBJECTIVES:

I. Financial toxicity will be assessed at the end of radiation treatment. II. Financial health care expenditure will be assessed at the end of radiation treatment III. Late toxicity.

CORRELATIVE RESEARCH OBJECTIVES:

I. Biopsies of enrolled patients will be evaluated for pathological assessment of cellular and genetic mutations to correlate them with disease local relapse and radiation resistance.

II. Patients will have their baseline positron emission tomography (PET)/computed tomography (CT) scan undergo auto-segmentation to calculate the functional imaging 18-fluoro-deoxyglucose (FDG) metabolic tumor volume (MTV), total lesions glycolysis (TLG) and maximum standardized uptake volume (SUVmax) of the sites to be treated with involved-site radiation therapy (ISRT) using MIMvista platform to correlate it with disease local relapse and treatment response.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo reduced dose ISRT once daily (QD) over 3, 2, or 5 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

ARM II: Patients undergo standard of care (SOC) radiation therapy QD over 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

After completion of study treatment, patients are followed up at days 7 and 14, months 3 and 6, and then every 6 months for up to 2 years post-radiation therapy.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

112

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85259
        • Rekruttering
        • Mayo Clinic in Arizona
        • Kontakt:
        • Ledende efterforsker:
          • William G. Rule, MD
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224-9980
        • Rekruttering
        • Mayo Clinic in Florida
        • Kontakt:
        • Ledende efterforsker:
          • Brad S. Hoppe, MD, MPH
    • Minnesota
      • Albert Lea, Minnesota, Forenede Stater, 56007
        • Rekruttering
        • Mayo Clinic Health System in Albert Lea
        • Kontakt:
        • Ledende efterforsker:
          • John Yeakel, MD
      • Mankato, Minnesota, Forenede Stater, 56001
        • Trukket tilbage
        • Mayo Clinic Health System - Mankato
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic in Rochester
        • Kontakt:
        • Ledende efterforsker:
          • Scott C. Lester, MD
    • Wisconsin
      • Eau Claire, Wisconsin, Forenede Stater, 54701
        • Rekruttering
        • Mayo Clinic Health System-Eau Claire Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Now Bahar Alam, MD
      • La Crosse, Wisconsin, Forenede Stater, 54601
        • Rekruttering
        • Mayo Clinic Health System-Franciscan Healthcare
        • Kontakt:
        • Ledende efterforsker:
          • Abigail L. Stockham, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years

  • Histological confirmation of indolent B-cell lymphoma that can include any of the following:

    • Follicular lymphoma (grade 1 or 2 or 3A)
    • Marginal zone lymphoma (nodal or extranodal)
    • Follicle center lymphoma
  • Any stage disease

  • Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3

  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only

  • Provide written informed consent

  • Ability to complete questionnaire(s) by themselves or with assistance

  • Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items

  • Confirmation from radiation oncologist of suitability to participate in study

Exclusion Criteria:

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Women of childbearing potential who are unwilling to employ adequate contraception
  • T-cell lymphoma

  • Receiving treatment for small and chronic lymphocytic lymphoma

  • Grade 3B follicular lymphoma

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ARM 1 (reduced dose ISRT)

Patients undergo reduced dose ISRT once daily (excluding weekends): 9 Gy delivered in 3 treatment fractions or 8 Gy in 2 fractions. At physician discretion, patients may receive 10 Gy in 5 fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

Ancillary studies

Undergo CT or PET/CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning

Undergo PET/CT

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • proton magnetisk resonans spektroskopisk billeddannelse
  • PT
  • Positron emissionstomografi (procedure)

Undergo endoscopy

Andre navne:
  • ES
  • Endoskopi
  • Endoskopisk undersøgelse

Undergo ISRT in 3 fractions

Andre navne:
  • ISRT
Aktiv komparator: ARM 2 (SOC ISRT)

Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends): 24 Gy in 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.

Ancillary studies

Undergo CT or PET/CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning

Undergo PET/CT

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • proton magnetisk resonans spektroskopisk billeddannelse
  • PT
  • Positron emissionstomografi (procedure)

Undergo endoscopy

Andre navne:
  • ES
  • Endoskopi
  • Endoskopisk undersøgelse

Undergo ISRT in 12 fractions

Andre navne:
  • ISRT

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of grade 2 or higher acute adverse events (AEs)
Tidsramme: Up to 14 days after radiation treatment

AEs will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Acute toxicity will be reported as a proportion calculated as the number of patients with acute toxicity divided by the total number of treatment patients. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 14 days after radiation treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Response rate
Tidsramme: Up to 3 months after radiation treatment

Response rate will be defined as the proportion of patients displaying response (complete response or partial response) at 3 months post treatment. Complete response is defined as the disappearance of all signs of cancer in response to treatment. Partial response is defined decrease in the size of target lesions by ≥ 50%, with no increase in the size of any lesion and no appearance of new lesions. Treated patients who do not have a 3-month evaluation will be classified as a non-response. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 3 months after radiation treatment
Time to progression rate
Tidsramme: Up to 24 months after radiation treatment

Local control will be defined as the number of days from end of radiation treatment until first local recurrence within 24 months post radiation treatment. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 24 months after radiation treatment
Patient reported quality of life
Tidsramme: Up to 3 months after radiation treatment

Patient reported quality of life will be measured using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale, a 13-item questionnaire answered on a scale of 1-5 where 1=Not at all and 5=Very much. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).

Up to 3 months after radiation treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Brad S. Hoppe, MD, MPH, Mayo Clinic

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. maj 2024

Primær færdiggørelse (Anslået)

30. maj 2029

Studieafslutning (Anslået)

30. maj 2031

Datoer for studieregistrering

Først indsendt

23. april 2024

Først indsendt, der opfyldte QC-kriterier

23. april 2024

Først opslået (Faktiske)

26. april 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • MC230808
  • 23-010273 (Anden identifikator: Mayo Clinic Institutional Review Board)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .